258 related articles for article (PubMed ID: 27151986)
1. Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.
Shcherbinin S; Schwarz AJ; Joshi A; Navitsky M; Flitter M; Shankle WR; Devous MD; Mintun MA
J Nucl Med; 2016 Oct; 57(10):1535-1542. PubMed ID: 27151986
[TBL] [Abstract][Full Text] [Related]
2. Kinetic Modeling of the Tau PET Tracer
Barret O; Alagille D; Sanabria S; Comley RA; Weimer RM; Borroni E; Mintun M; Seneca N; Papin C; Morley T; Marek K; Seibyl JP; Tamagnan GD; Jennings D
J Nucl Med; 2017 Jul; 58(7):1124-1131. PubMed ID: 27908967
[No Abstract] [Full Text] [Related]
3. Pharmacokinetic Evaluation of the Tau PET Radiotracer
Wooten DW; Guehl NJ; Verwer EE; Shoup TM; Yokell DL; Zubcevik N; Vasdev N; Zafonte RD; Johnson KA; El Fakhri G; Normandin MD
J Nucl Med; 2017 Mar; 58(3):484-491. PubMed ID: 27660144
[No Abstract] [Full Text] [Related]
4. Modeling Strategies for Quantification of In Vivo
Hahn A; Schain M; Erlandsson M; Sjölin P; James GM; Strandberg OT; Hägerström D; Lanzenberger R; Jögi J; Olsson TG; Smith R; Hansson O
J Nucl Med; 2017 Apr; 58(4):623-631. PubMed ID: 27765859
[TBL] [Abstract][Full Text] [Related]
5. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
6. Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with
Lohith TG; Bennacef I; Vandenberghe R; Vandenbulcke M; Salinas CA; Declercq R; Reynders T; Telan-Choing NF; Riffel K; Celen S; Serdons K; Bormans G; Tsai K; Walji A; Hostetler ED; Evelhoch JL; Van Laere K; Forman M; Stoch A; Sur C; Struyk A
J Nucl Med; 2019 Jan; 60(1):107-114. PubMed ID: 29880509
[No Abstract] [Full Text] [Related]
7. Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.
Jonasson M; Wall A; Chiotis K; Saint-Aubert L; Wilking H; Sprycha M; Borg B; Thibblin A; Eriksson J; Sörensen J; Antoni G; Nordberg A; Lubberink M
J Nucl Med; 2016 Apr; 57(4):574-81. PubMed ID: 26795290
[TBL] [Abstract][Full Text] [Related]
8. Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.
Baker SL; Lockhart SN; Price JC; He M; Huesman RH; Schonhaut D; Faria J; Rabinovici G; Jagust WJ
J Nucl Med; 2017 Feb; 58(2):332-338. PubMed ID: 27587706
[TBL] [Abstract][Full Text] [Related]
9. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
[TBL] [Abstract][Full Text] [Related]
10. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [
Guehl NJ; Wooten DW; Yokell DL; Moon SH; Dhaynaut M; Katz S; Moody KA; Gharagouzloo C; Kas A; Johnson KA; El Fakhri G; Normandin MD
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2099-2111. PubMed ID: 31332496
[TBL] [Abstract][Full Text] [Related]
12. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
13. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA
J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675
[TBL] [Abstract][Full Text] [Related]
14. Characterization of 3 Novel Tau Radiopharmaceuticals,
Wong DF; Comley RA; Kuwabara H; Rosenberg PB; Resnick SM; Ostrowitzki S; Vozzi C; Boess F; Oh E; Lyketsos CG; Honer M; Gobbi L; Klein G; George N; Gapasin L; Kitzmiller K; Roberts J; Sevigny J; Nandi A; Brasic J; Mishra C; Thambisetty M; Mogekar A; Mathur A; Albert M; Dannals RF; Borroni E
J Nucl Med; 2018 Dec; 59(12):1869-1876. PubMed ID: 29728519
[No Abstract] [Full Text] [Related]
15. Tau PET imaging with
Mueller A; Bullich S; Barret O; Madonia J; Berndt M; Papin C; Perrotin A; Koglin N; Kroth H; Pfeifer A; Tamagnan G; Seibyl JP; Marek K; De Santi S; Dinkelborg LM; Stephens AW
J Nucl Med; 2020 Jun; 61(6):911-919. PubMed ID: 31712323
[No Abstract] [Full Text] [Related]
16. In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand
Betthauser TJ; Cody KA; Zammit MD; Murali D; Converse AK; Barnhart TE; Stone CK; Rowley HA; Johnson SC; Christian BT
J Nucl Med; 2019 Jan; 60(1):93-99. PubMed ID: 29777006
[TBL] [Abstract][Full Text] [Related]
17. Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.
Lockhart SN; Baker SL; Okamura N; Furukawa K; Ishiki A; Furumoto S; Tashiro M; Yanai K; Arai H; Kudo Y; Harada R; Tomita N; Hiraoka K; Watanuki S; Jagust WJ
PLoS One; 2016; 11(6):e0158460. PubMed ID: 27355840
[TBL] [Abstract][Full Text] [Related]
18. Tau positron emission tomographic imaging in aging and early Alzheimer disease.
Johnson KA; Schultz A; Betensky RA; Becker JA; Sepulcre J; Rentz D; Mormino E; Chhatwal J; Amariglio R; Papp K; Marshall G; Albers M; Mauro S; Pepin L; Alverio J; Judge K; Philiossaint M; Shoup T; Yokell D; Dickerson B; Gomez-Isla T; Hyman B; Vasdev N; Sperling R
Ann Neurol; 2016 Jan; 79(1):110-9. PubMed ID: 26505746
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of
Bullich S; Barret O; Constantinescu C; Sandiego C; Mueller A; Berndt M; Papin C; Perrotin A; Koglin N; Kroth H; Pfeifer A; Tamagnan G; Madonia J; Seibyl JP; Marek K; De Santi S; Dinkelborg LM; Stephens AW
J Nucl Med; 2020 Jun; 61(6):920-927. PubMed ID: 31712324
[No Abstract] [Full Text] [Related]
[Next] [New Search]
